Technical Data Sheet

Cerebrolysin

Also Known As: FPF-1070, Cerebrolysin injection, Porcine brain peptide hydrolysate, Brain peptide mixture, Neurotrophic peptide mixture, EVER Neuro Pharma cerebrolysin, Cerebrolysin infusion, Cerebrolysin neuropeptides, Neurotrophic factor mimetic blend, BDNF NGF mimetic cerebrolysin, Cerebrolysin stroke treatment, neurotrophic peptide, porcine brain extract

Scan To View Profile

Evidence Tier	Approved Drug
Category	Immunity & Wellness
Class	Porcine brain-derived standardized peptide hydrolysate (<10 kDa peptides); neurotrophic factor mimetic
Molecular Target	BDNF/TrkB pathway; NGF/TrkA pathway; anti-apoptotic (Bcl-2 upregulation); antioxidant; glutamate excitotoxicity protection
Sequence	standardized peptide mixture (<10 kDa)
Molecular Weight	mixture
CAS	not applicable
Parent	Porcine brain proteins
Mechanism	It delivers a mix of tiny proteins directly to the brain that mimic natural growth signals. These signals protect nerve cells from dying and encourage them to grow new branches.
Studied For	Acute ischemic stroke recovery, Traumatic brain injury (TBI), Vascular dementia, Alzheimer's-type dementia, Cognitive impairment recovery, Neuroprotection, Neuroregeneration, BDNF and NGF pathway stimulation, Post-stroke rehabilitation, Parkinson's disease research, ADHD research, Memory enhancement, Anti-apoptotic neuronal protection, Neuroplasticity promotion, Spine injury models, Cerebral ischemia protection, Age-related cognitive decline, TBI recovery, Alzheimer's research, dementia, neurogenesis, stroke recovery, cognitive decline, neurological repair
Administration Route	Injection Only
Form	sterile aqueous solution (not lyophilized)
Diluent	used as-is
Storage Temperature	protect from light
Light Sensitive	Yes
Freeze / Thaw	n/a
Handling Notes	Do not co-infuse with amino-acid solutions; batch variability.
Regulatory	Approved in many EU/Asia/CIS countries; not FDA-approved.
Sources